zoledronic acid has been researched along with celecoxib in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Anderson, J; Clarke, NW; Dearnaley, DP; Dwyer, J; James, ND; Mason, MD; Masters, J; Morgan, RC; Parmar, MK; Popert, RJ; Sanders, K; Stansfeld, J; Sydes, MR | 2 |
| Balbontín-Ayala, F; Cañigral, A; Carlos, Fd; Cobo, T; Fernández-González, FJ; Fernández-Vázquez, JP; Gonzalo-Orden, JM; Sánchez-Lasheras, F; Vega, JA | 1 |
| Assi, T; Bachour, M; El Rassy, E; Farhat, F; Ghosn, M; Kattan, J | 1 |
| Saad, F | 1 |
| Attard, G; Barber, J; Cassoly, E; Clarke, NW; Cross, W; Dearnaley, DP; Gilson, C; Ibrahim, A; James, ND; Jones, RJ; Logue, J; Lydon, A; Mason, MD; Matheson, D; Millman, R; Nikapota, AD; O'Sullivan, JM; Parker, CC; Parmar, MKB; Porfiri, E; Protheroe, A; Rentsch, CA; Ritchie, AWS; Russell, JM; Schiavone, F; Spears, MR; Srihari, NN; Sydes, MR; Thalmann, GN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C | 1 |
| Chouahnia, K; Culine, S; Fossey-Diaz, V; Guetz, GD; Landre, T; Taleb, C | 1 |
| Griebling, TL | 1 |
4 review(s) available for zoledronic acid and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Remodeling; Celecoxib; Clodronic Acid; Diclofenac; Diphosphonates; Humans; Imidazoles; Interferon-gamma; Isoxazoles; Lactones; Mice; Orthodontic Anchorage Procedures; Osteoclasts; Osteoprotegerin; Pamidronate; Rats; Resveratrol; Stilbenes; Sulfones; Tooth Mobility; Tooth Movement Techniques; Zoledronic Acid | 2015 |
Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prostatic Neoplasms; Retreatment; Treatment Outcome; Zoledronic Acid | 2016 |
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2019 |
3 trial(s) available for zoledronic acid and celecoxib
| Article | Year |
|---|---|
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrazoles; Risk Factors; Sulfonamides; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diphosphonates; Docetaxel; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Celecoxib; Diphosphonates; Disease-Free Survival; Early Termination of Clinical Trials; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Lymphatic Metastasis; Male; Middle Aged; Orchiectomy; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Time Factors; Zoledronic Acid | 2017 |
4 other study(ies) available for zoledronic acid and celecoxib
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Taxoids; Zoledronic Acid | 2008 |
Bone-Targeted Therapy in Prostate Cancer in 2017: Lost Opportunities, Confusion, and Controversy.
Topics: Celecoxib; Diphosphonates; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2017 |
Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
Topics: Androstenes; Celecoxib; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2020 |